VIDEO: Oral therapies in pediatric, adolescent psoriasis

In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025.

“From a systemic agent standpoint, we’ve never had an oral agent approved for psoriasis,” Eichenfield, who is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and vice chair of the department of dermatology at University of California, San Diego, told Healio. “We’ve used methotrexate and cyclosporine as unapproved agents, but not as readily in pediatrics and adolescents.”

Eichenfield, who also serves as a member of the Healio Dermatology Peer Perspective Board, also discussed the use of interleukin (IL)-17 and IL-23 inhibitors.

“One of the other things that people are looking forward to is the new oral IL-23 receptor agonist peptide icotrokinra [JNJ-2113; Protagonist Therapeutics, Johnson & Johnson],” Eichenfield said. “Adult data have been presented, but we know that there are studies including patients 12 and older.”